CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab

Conditions:   Intermediate Stage of Hepatocellular Carcinoma;   Hepatocellular Carcinoma Interventions:   Drug: Durvalumab;   Drug: Tremelimumab 300 mg;   Drug: Tremelimumab 75 mg Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials